HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Pooja P. Advani, Jennifer A. Crozier, Edith A. Perez

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.

Original languageEnglish (US)
Pages (from-to)35-49
Number of pages15
JournalBiomarkers in Medicine
Issue number1
StatePublished - Jan 1 2015


  • American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • HER2 testing
  • breast cancer
  • immunohistochemistry (IHC)
  • in situ hybridization (ISH)
  • trastuzumab

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'HER2 testing and its predictive utility in anti-HER2 breast cancer therapy'. Together they form a unique fingerprint.

Cite this